Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.78 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | PKM | P14618 | 1/20 | 0.78 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.75 |
| ▸ | CNR2 | P34972 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | PTGES | O14684 | 1/20 | 0.74 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ALB | P02768 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31570804 | 0.92 | PTGS2 (0.75) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL12989547 | 0.90 | PTGS2 (0.77) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL11614146 | 0.89 | PTGS2 (0.83) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL4549122 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| Acemetacin SCHEMBL23843 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| Acemetacin SCHEMBL29402955 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL29855593 | 0.88 | PTGS2 (0.86) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL12988768 | 0.88 | PTGS2 (0.86) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| SCHEMBL11568121 | 0.87 | PTGS2 (0.89) | PTGS2PTGS1GLO1HIF1AHTR1A | |
| Acemetacin SCHEMBL10910170 | 0.87 | PTGS2 (0.98) | PTGS2PTGS1GLO1HIF1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117114959-B | Image encryption method based on key feedback mechanism of multi-parameter one-dimensional chaotic system | 山东青橙数字科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-113754614-B | Preparation method of 7-methoxy docetaxel | 无锡紫杉药业有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-116041438-A | Programmed death-ligand 1 targeting peptide PET molecular probe and application thereof | 江苏省原子医学研究所 | 2023-05-02 | — | — | CN | claimed |
| WO-2025231521-A1 | COMPOUNDS AND THEIR USES | NEWERA.BIO PTY LTD (AU) | 2025-11-13 | — | — | WO | disclosed |
| EP-4553084-A2 | USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS | Ethris GmbH (DE) | 2025-05-14 | — | — | EP | disclosed |
| US-20250109186-A1 | SARS-CoV-2 BINDING PROTEINS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-04-03 | — | — | US | disclosed |
| CN-119431318-A | Organic compound, organic electroluminescent device and electronic device comprising the same | 陕西莱特光电材料股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4487870-A2 | VIDOFLUDIMUS FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL DISEASES | Immunic AG (DE) | 2025-01-08 | — | — | EP | disclosed |
| EP-4240396-B1 | IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS | ETHRIS GMBH (DE) | 2025-01-01 | — | — | EP | disclosed |
| US-12167994-B2 | Vidofludimus for use in the treatment or prevention of viral diseases | IMMUNIC AG (DE) | 2024-12-17 | — | — | US | disclosed |
| CN-119118846-A | Organic compound, and electronic component and electronic device using same | 陕西莱特光电材料股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2022206493-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT COMPRISING SAID ORGANIC COMPOUND, AND ELECTRONIC APPARATUS | 陕西莱特光电材料股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| WO-2022189379-A1 | TREATMENT OF CORONAVIRUS INFECTIONS USING SAM CYCLE INHIBITORS | Technische Universität München (DE) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022188514-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT COMPRISING SAME, AND ELECTRONIC DEVICE | 陕西莱特光电材料股份有限公司 | 2022-09-15 | — | — | WO | disclosed |
| CN-114878703-A | Method for determining substance related to gamithromycin | 浙江国邦药业有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-11376232-B2 | Vidofludimus for use in the treatment or prevention of viral diseases | IMMUNIC AG (DE) | 2022-07-05 | — | — | US | disclosed |
| CN-112110898-B | Synephrine sulfonylation derivative and intermediate, preparation method and application thereof | 西南大学 | 2022-07-05 | — | — | CN | disclosed |
| WO-2022096582-A1 | USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS | ETHRIS GMBH (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022081920-A1 | SYSTEMS FOR AND METHODS OF TREATMENT SELECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022042267-A1 | NITROGEN-CONTAINING COMPOUND, ELECTRONIC COMPONENT, AND ELECTRONIC DEVICE | 陕西莱特迈思光电材料有限公司 | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12167994-B2 | Vidofludimus for use in the treatment or prevention of viral diseases | DHODH, ACE2, DPYD | PTGS2 1473/4885PTGS1 2325/4885GLO1 253/4885 |
| US-11376232-B2 | Vidofludimus for use in the treatment or prevention of viral diseases | DHODH, ACE2, DPYD | PTGS2 1473/4885PTGS1 2325/4885GLO1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.